Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Cells navigating in complex microenvironments frequently encounter narrow spaces that physically challenge migration.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

Dana-Farber researchers identified factors predicting the success of donor lymphocyte infusion (DLI) in treating relapsed AML. They found that specific CD8+ T cells with high ZNF683/Hobit expression ...

Columbia team uncovers key immune cells for treating relapsed acute Myeloid Leukemia ... The current treatment for relapsed AML, donor lymphocyte infusion (DLI)--a therapy involving donor ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...